HIGH QUALITY SCIENTIFIC CONTENT,  ONLINE OPEN ACCESS,  GLOBAL SCIENTIFIC AUDIENCE,  COST EFFECTIVE, ANY ONE CAN DOWNLOAD REPRINTS 
Spreading knowledge

Google Scholar

Google Scholar

Archives

Back 

EDITORIAL -VOL. 3, ISSUE 4

EDITORIAL

Generic pharmaceutical market growth is a reality and important in both of the aspects, one economical availability of the drugs and second competition that guides quality of the products. Concern with generic product is that whether their quality is similar to the innovator product and to establish it is mandatory for generic manufacturer to establish Bioequivalence of its product with innovator product.
The United States Food and Drug Administration (FDA) has defined bioequivalence as, "the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.

In this issue, we are presenting two publication on bioequivalence of two formulations Rabeprazole (EC) And Domperidone(SR), and Isoxsuprine Hcl 40 Mg (SR) Capsules.

We hope readers and contributor will also like the content of this issue.
Sincerely
J.N. Singh
Attachments:
Time to create page: 0.12 seconds


Copyright © All rights reserved Science Instinct Publications sciipub.com